Literature DB >> 17846022

HLA-G expression in human ovarian carcinoma counteracts NK cell function.

A Lin1, W-H Yan, H-H Xu, M-F Gan, J-F Cai, M Zhu, M-Y Zhou.   

Abstract

BACKGROUND: Human leukocyte antigen-G (HLA-G) is an important immunotolerant which could be a part of the strategies applied by malignant cells applied to avoid host immunosurveillance. Aberrant expression of HLA-G has been found in ovarian carcinoma. The aim of this study was to evaluate the HLA-G expression in ovarian cancer tissues and to explore its function in vitro.
MATERIALS AND METHODS: HLA-G expression in 33 primary ovarian carcinoma tissues was analyzed using immunohistochemistry with the anti-HLA-G monoclonal antibody (mAb) 4H84. Furthermore, the function of HLA-G in NK cell cytotoxicity was determined in vitro by cloning and expression of HLA-G on the ovarian carcinoma cell OVCAR-3.
RESULTS: HLA-G expression was detected in 22/33 (66.7%) primary tumor tissues, but was absent in normal ovarian tissues (P<0.01). Cytotoxicity studies showed that HLA-G expression dramatically inhibits cell lyses by NK-92 cells (P<0.01), which could be restored by the anti-HLA-G conformational mAb 87G (P<0.01).
CONCLUSION: HLA-G was expressed in a significant number of primary ovarian carcinoma tissues, and HLA-G expression in OVCAR-3 could directly inhibit NK-92 cell lysis. Taken together, our results indicated that expression of HLA-G plays an important role in evasion of ovarian cancer cells from host immunosurveillance.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17846022     DOI: 10.1093/annonc/mdm356

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  32 in total

Review 1.  A review of the evolution of viviparity in squamate reptiles: the past, present and future role of molecular biology and genomics.

Authors:  Bridget F Murphy; Michael B Thompson
Journal:  J Comp Physiol B       Date:  2011-05-15       Impact factor: 2.200

2.  Flow cytometry-based assessment of direct-targeting anti-cancer antibody immune effector functions.

Authors:  Michelle L Miller; Olivera J Finn
Journal:  Methods Enzymol       Date:  2019-08-12       Impact factor: 1.600

Review 3.  Monoclonal antibodies for the treatment of cancer.

Authors:  Casey W Shuptrine; Rishi Surana; Louis M Weiner
Journal:  Semin Cancer Biol       Date:  2012-01-08       Impact factor: 15.707

Review 4.  Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape.

Authors:  Robert L Ferris; Elizabeth M Jaffee; Soldano Ferrone
Journal:  J Clin Oncol       Date:  2010-08-09       Impact factor: 44.544

Review 5.  Use of allogeneic NK cells for cancer immunotherapy.

Authors:  Melissa A Geller; Jeffrey S Miller
Journal:  Immunotherapy       Date:  2011-12       Impact factor: 4.196

6.  IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer.

Authors:  M Felices; S Chu; B Kodal; L Bendzick; C Ryan; A J Lenvik; K L M Boylan; H C Wong; A P N Skubitz; J S Miller; M A Geller
Journal:  Gynecol Oncol       Date:  2017-02-22       Impact factor: 5.482

7.  Human Leukocyte Antigen-G (HLA-G) Expression in Cancers: Roles in Immune Evasion, Metastasis and Target for Therapy.

Authors:  Aifen Lin; Wei-Hua Yan
Journal:  Mol Med       Date:  2015-08-24       Impact factor: 6.354

Review 8.  Intracellular antigens as targets for antibody based immunotherapy of malignant diseases.

Authors:  Yangyang Wang; Xinhui Wang; Cristina R Ferrone; Joseph H Schwab; Soldano Ferrone
Journal:  Mol Oncol       Date:  2015-10-30       Impact factor: 6.603

Review 9.  HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance.

Authors:  M Campoli; S Ferrone
Journal:  Oncogene       Date:  2008-10-06       Impact factor: 9.867

10.  Comprehensive Transcriptomic Analysis Reveals the Role of the Immune Checkpoint HLA-G Molecule in Cancers.

Authors:  Hui-Hui Xu; Jun Gan; Dan-Ping Xu; Lu Li; Wei-Hua Yan
Journal:  Front Immunol       Date:  2021-07-01       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.